Watson beefs up R&D effort with $305M women's health buyout

Watson will gain late-stage contraceptive and fertility drugs in a buyout of Uteron Pharma--courtesy of Uteron Pharma With an eye to boosting its pipeline of experimental drugs for women's health, generics giant Watson Pharmaceuticals ($WPI) has swooped in and acquired Belgium's Uteron Pharma in a $305 million deal. The buyout gives Watson a pair of late-stage contraceptive and fertility drugs...